Summary
Flex4Pharma has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €30,751 and a net result of €18,711, of which €14,500 non-recurring income. Equity is growing by about 24% per year across the filed financial years. Its solvency ranks better than 66% of 22,581 sector peers (NACE 47, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
- Equity
- €30,751
- Profit
- €18,711
- Holdings
- 1
SignalsneutralLatest accounts filed on timeShow the evidence
Checked score
This is a financial institution (bank, insurer or financial holding). A bank balance sheet works differently from that of an ordinary trading or manufacturing company. We therefore show no bankruptcy probability rather than a misleading figure.
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
This company filed its last 6 accounts on average 23 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
- Annual accounts filedfinancial year 2025 · micro…
- Annual accounts filedfinancial year 2024 · micro…
- Back to profitnet €718
Financials · financial year 2025, micro format
2021 to 2025, 5 financial years 2020 to 2025, 6 financial years
The operating result returns to profit in 2025: €26,632 after a loss of €205 in 2024.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 47, Retail trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | - | €14,500 | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | - | €380 | €428 | €428 | €428 | €428 | = |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | €5,046 | - | - | - | - |
| Other operating charges640/8 | - | €482 | €405 | €448 | €451 | €465 | ▲ 3.2% |
| Gross operating margin9900 | -€4,335 | €5,081 | €39,332 | -€373 | €674 | €27,525 | ▲ 41× |
| Operating profit (loss)9901 | -€4,822 | €4,219 | €33,454 | -€1,249 | -€205 | €26,632 | - |
| Financial income75/76B | - | €0 | €1,232 | €772 | €1,037 | €0 | ▼ 100% |
| Recurring financial income75 | €0 | €0 | €1,232 | €772 | €1,037 | €0 | ▼ 100% |
| Financial charges65/66B | - | €191 | €245 | €1,318 | €113 | €297 | ▲ 162% |
| Recurring financial charges65 | €53 | €191 | €245 | €1,318 | €113 | €297 | ▲ 162% |
| Profit (loss) for the period before taxes9903 | -€4,874 | €4,028 | €34,441 | -€1,794 | €718 | €26,335 | ▲ 37× |
| Income taxes67/77 | - | - | €8,479 | - | - | €7,624 | - |
| Profit (loss) for the period9904 | -€4,874 | €4,028 | €25,962 | -€1,794 | €718 | €18,711 | ▲ 26× |
| Profit (loss) for the period to be appropriated9905 | -€4,874 | €4,028 | €25,962 | -€1,794 | €718 | €18,711 | ▲ 26× |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Total assets20/58 | €17,300 | €17,839 | €44,486 | €31,292 | €29,055 | €59,511 | ▲ 105% |
| Fixed assets21/28 | - | €1,759 | €1,331 | €904 | €976 | €30,048 | ▲ 31× |
| Tangible fixed assets22/27 | - | €1,759 | €1,331 | €904 | €476 | €48 | ▼ 89.9% |
| Furniture and vehicles24 | - | €1,759 | €1,331 | €904 | €476 | €48 | ▼ 89.9% |
| Financial fixed assets28 | - | - | - | - | €500 | €30,000 | ▲ 60× |
| Current assets29/58 | €17,300 | €16,080 | €43,155 | €30,389 | €28,079 | €29,462 | ▲ 4.9% |
| Stocks and contracts in progress3 | €6,428 | €5,500 | - | - | - | - | - |
| Stocks30/36 | - | €5,500 | - | - | - | - | - |
| Amounts receivable within one year40/41 | €7,396 | €6,327 | €21,893 | €22,801 | €22,508 | €24,845 | ▲ 10.4% |
| Trade receivables40 | - | €5,730 | €1,743 | €1,255 | €7,905 | €6,630 | ▼ 16.1% |
| Other amounts receivable41 | - | €597 | €20,150 | €21,546 | €14,603 | €18,215 | ▲ 24.7% |
| Cash at bank and in hand54/58 | €1,842 | €3,582 | €20,484 | €6,519 | €4,255 | €4,273 | ▲ 0.4% |
| Deferred charges and accrued income490/1 | - | €671 | €777 | €1,068 | €1,316 | €345 | ▼ 73.8% |
| Equity and liabilities | |||||||
| Total equity and liabilities10/49 | €17,300 | €17,839 | €44,486 | €31,292 | €29,055 | €59,511 | ▲ 105% |
| Equity10/15 | -€1,874 | €2,154 | €28,116 | €26,321 | €27,040 | €30,751 | ▲ 13.7% |
| Contributions10/11 | - | €3,000 | €3,000 | €3,000 | €3,000 | €3,000 | = |
| Reserves13 | - | - | €25,116 | €23,321 | €24,040 | €27,751 | ▲ 15.4% |
| Distributable reserves133 | - | - | €25,116 | €23,321 | €24,040 | €27,751 | ▲ 15.4% |
| Profit (loss) carried forward14 | -€4,874 | -€846 | - | - | - | €0 | - |
| Amounts payable17/49 | €19,174 | €15,685 | €16,370 | €4,971 | €2,015 | €28,760 | ▲ 14× |
| Amounts payable within one year42/48 | €18,174 | €15,685 | €12,896 | €4,874 | €2,015 | €28,760 | ▲ 14× |
| Financial debts43 | - | - | - | - | - | €1,688 | - |
| Credit institutions430/8 | - | - | - | - | - | €1,688 | - |
| Trade debts44 | €10,811 | €4,547 | - | €51 | €308 | €6,677 | ▲ 22× |
| Suppliers440/4 | - | €4,547 | - | €51 | €308 | €6,677 | ▲ 22× |
| Taxes, remuneration and social security45 | - | - | €3,600 | €4,823 | €300 | €2,624 | ▲ 775% |
| Taxes450/3 | - | - | €3,600 | €4,823 | €300 | €2,624 | ▲ 775% |
| Other amounts payable47/48 | - | €11,138 | €9,296 | - | €1,407 | €17,770 | ▲ 13× |
| Accrued charges and deferred income492/3 | - | - | €3,474 | €97 | - | - | - |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€4,874 | €4,028 | €25,962 | -€1,794 | €718 | €18,711 | ▲ 26× |
| + Depreciation and write-downs630 | - | €380 | €428 | €428 | €428 | €428 | = |
| Operating cash flow (approximation) | -€4,874 | €4,408 | €26,390 | -€1,367 | €1,146 | €19,139 | ▲ 17× |
| Investment in fixed assets (approximation) | - | - | €0 | €0 | -€500 | -€29,500 | ▼ 5,800% |
| Change in cash | - | €1,740 | €16,902 | -€13,965 | -€2,264 | €18 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (6)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | micro format | 06-07-2026 | 2026-00255679 |
| 31-12-2024 | micro format | 16-07-2025 | 2025-00273972 |
| 31-12-2023 | micro format | 12-07-2024 | 2024-00242170 |
| 31-12-2022 | micro format | 29-06-2023 | 2023-00174732 |
| 31-12-2021 | micro format | 06-07-2022 | 2022-20150075 |
| 31-12-2020 | micro format | 09-07-2021 | 2021-33400165 |
Similar companies · same sector, comparable size
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Owners and capital
Owners
No owners or capital events in the accounts and acts we read.
Group and network
Holdings and subsidiaries
1 holdingHoldings 1
- AixofitFRSourceown accounts 202550%
According to the 2025 annual accounts of Flex4Pharma and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
No directors read yet: 0 of 1 Gazette act processed.
History
Acts, filings and financial milestones
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Register details
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 27 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
1 establishment unit
1 parcel
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 23062B0138/00D003 | Flanders | 637 m² | 1 · 160 m² | 7.2 m · 2 |